Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. reports news on its life science research and clinical diagnostics products, including instruments, reagents, test systems, specialized quality controls, blood typing, diabetes products, infectious disease products, and Droplet Digital PCR technologies.
Company updates commonly cover quarterly and annual financial results, Clinical Diagnostics and Life Science segment trends, currency and end-market conditions, product portfolio developments, share repurchases, earnings calls, and healthcare investor conferences. Bio-Rad’s customer base includes universities, research institutions, hospitals, biopharmaceutical companies, and clinical, food safety, and environmental quality laboratories.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bio-Rad Laboratories, Inc. (NYSE: BIO.B) will release its first-quarter 2023 financial results on May 4, 2023, after market close. A conference call is scheduled for 2 PM Pacific Time to discuss these results, with participation details available. Bio-Rad is recognized as a leader in life science research and clinical diagnostics, with a revenue of $2.8 billion in 2022. The company serves a wide range of customers including universities, hospitals, and biotech firms globally. For more information, the company’s Investor Relations section offers access to the webcast of the call. This will provide insights into the company’s performance and strategic direction as it progresses through the fiscal year.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) announced its participation in a fireside chat at Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference. The event is scheduled for Thursday, March 2, 2023, at 11:45 AM Eastern Time (8:45 AM Pacific Time). A live webcast and replay will be available on the Investor Relations section of Bio-Rad's website. With over 70 years of expertise, Bio-Rad leads in life science research and clinical diagnostics, serving various sectors including healthcare and biotechnology. The company had approximately $2.8 billion in revenues in 2022, employing around 8,300 staff worldwide.
Bio-Rad Laboratories (BIO, BIOb) reported Q4 2022 net sales of $730.3 million, down 0.3% from Q4 2021, primarily due to a significant drop in COVID-related revenue. Life Science sales rose 10.1%, while Clinical Diagnostics declined 8.7%. Net income surged to $827.7 million, or $27.78 per share, from a net loss of $1.57 billion in Q4 2021, driven by fair market value changes in equity securities. For FY 2022, total sales decreased 4.1% to $2.8 billion, with a net loss of $3.63 billion. The company projects 6-7% non-GAAP currency-neutral revenue growth in 2023, citing a strong market recovery and operational improvements.
Element Biosciences and Bio-Rad Laboratories have announced a partnership to advance RNA sequencing through the integration of Bio-Rad's SEQuoia RNA Sequencing Library Preparation portfolio with Element's AVITI™ Benchtop Sequencer. This collaboration aims to enhance RNA sequencing accuracy and efficiency, utilizing SEQuoia kits designed for various RNA inputs. The AVITI System offers unique capabilities, including two independent flow cells and up to 2 billion reads, ensuring high-quality data. Results from their collaboration will be presented at the AGBT General Meeting on February 9, 2023. This initiative positions both companies to deliver a cost-effective solution for genomic research.
Bio-Rad Laboratories, Inc. will report its financial results for Q4 and full year 2022 on February 16, 2023, post-market close. Management will host a conference call at 2 PM PT (5 PM ET) to discuss these results. Participants can dial 844-200-6205 in the U.S. or +1 929-526-1599 internationally, using access code: 143970. A live webcast will also be available on their website. Bio-Rad is recognized globally for developing and marketing life science and clinical diagnostic products, generating $2.9 billion in revenues as of 2021.